Key PointsRegulators in the U.S. extended the review period for Exelixis’ request to approve a new cancer drug.

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

ALAMEDA, Calif., October 15, 2026--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company’s website.

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

Exelixis (EXEL) is drawing attention after a year of strong share performance. The stock is up about 51% over the past 12 months and roughly 171% over three years. Recent trading in Exelixis has been relatively steady, with the share price at US$58.44 and short term moves broadly flat. However, the 1 year total shareholder return of 51.24% and 3 year total shareholder return of 171.81% indicate momentum that has built over time rather than faded. Scan other oncology and biotech players...

Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus?

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis, Inc. News